Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Artivion ( (AORT) ) has shared an announcement.
On May 7, 2026, Artivion reported first-quarter 2026 revenue of $116.3 million, up 18% year over year on a GAAP basis, with net income of $1.4 million and a 26% increase in adjusted EBITDA to $22.1 million. Management cited strong growth in stent grafts, On‑X valves, preservation services, and BioGlue, alongside continued enrollment in the ARTIZEN trial and robust adoption trends in AMDS and On‑X.
The company also disclosed that Endospan’s NEXUS Aortic Arch System received U.S. FDA PMA approval on April 2, 2026, and that on May 7, 2026 its Singapore subsidiary exercised a longstanding option to acquire Endospan for an expected net upfront cash consideration of about $135 million, plus up to $200 million in performance-based earnouts. While Artivion lowered its full-year 2026 revenue and adjusted EBITDA outlook due to transient operational factors and limited near-term NEXUS sales ahead of a planned January 1, 2027 U.S. launch, the deal is expected to significantly strengthen its aortic arch franchise and future growth profile.
The most recent analyst rating on (AORT) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.
Spark’s Take on AORT Stock
According to Spark, TipRanks’ AI Analyst, AORT is a Neutral.
The score is driven primarily by improving financial performance and a strong, margin-expansion-focused 2026 outlook from the earnings call. This is tempered by mixed cash-flow quality (free cash flow negative in 2025), bearish technical momentum, and limited valuation support from a negative P/E and no dividend yield data.
To see Spark’s full report on AORT stock, click here.
More about Artivion
Artivion, Inc., listed on the NYSE as AORT, is a cardiac and vascular surgery company focused on treating aortic disease through products such as stent grafts, the On-X mechanical heart valve, preservation services, and BioGlue surgical adhesive. The company is building a comprehensive aortic arch portfolio that includes AMDS, the NEXUS Aortic Arch System, and the Arcevo LSA platform, positioning it as a leading provider of endovascular and surgical solutions for complex aortic pathologies.
Average Trading Volume: 438,412
Technical Sentiment Signal: Buy
Current Market Cap: $1.68B
For an in-depth examination of AORT stock, go to TipRanks’ Overview page.